← Leaderboards
Anthony Andrew Oliva
Longeveron, Llc
$2,470,922
Attributed
$5,292,339
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2017–20$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$5,292,339 · 2
By mechanism
R44$4,240,853 · 1
R42$1,051,486 · 1
Top collaborators
- Joshua M Hare6 shared
- Sean X Leng3 shared
Others in their field
Other Emerging Leaders on “Cell Therapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$26,831,044
- Bronwen Shaw · Medical College Of Wisconsin$24,206,529
- Gary Fanger · Rise Therapeutics, Llc$20,770,458
Research focus
Cell TherapyPatient PopulationProgramsPlacebosSafetyWalkingFollow-UpInsightInternationalPhysical PerformanceAllogenicPropertySerumTnf GeneAffectClinical TrialsInflammatoryInflammationInterleukin-1Interleukin-6Mesenchymal Stem CellsStem Cell TherapyAnti-InflammatoryBlinded
Grant awards (6)
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$1,974,282
R44 · FY2020 · AG · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$435,997
R42 · FY2020 · AG
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$1,983,531
R44 · FY2019 · AG · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$465,489
R42 · FY2019 · AG
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$283,040
R44 · FY2018 · AG · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$150,000
R42 · FY2017 · AG